Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

Fujifilm and Abzena plan US biologic drug facilities

by Michael McCoy
January 23, 2021 | A version of this story appeared in Volume 99, Issue 3

 

Two contract manufacturers of biologic drugs plan significant investments in the US. Fujifilm says it will spend more than $2 billion to establish a large-scale cell culture site in the US by 2025. The Japanese firm is already spending almost $1 billion to double the size of a biologics plant in Denmark that it acquired from Biogen. Meanwhile, the British firm Abzena plans to build its sixth biologics plant, this one in the US.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.